Article

Generation of a NES-mScarlet Red Fluorescent Reporter Human iPSC Line for Live Cell Imaging and Flow Cytometric Analysis and Sorting Using CRISPR-Cas9-Mediated Gene Editing

Parivash Nouri 1, Anja Zimmer 2, Stefanie Brüggemann 1, Robin Friedrich 1, Ralf Kühn 2,* and Nilima Prakash 1,*

1 Laboratory of Applied Genetics and Stem Cell Biology, Department Hamm 2, Hamm-Lippstadt University of Applied Sciences, 59063 Hamm, Germany; Parivash.Nouri@hschl.de (P.N.); Stefanie.Brueggemann@stud.hschl.de (S.B.); Robin.Friedrich@stud.hschl.de (R.F.)
2 Genome Engineering & Disease Models, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany; Anja.Zimmer@mdc-berlin.de
* Correspondence: Ralf.Kuehn@mdc-berlin.de (R.K.); Nilima.Prakash@hschl.de (N.P.); Tel.: +49-30-9406-2832 (R.K.); +49-2381-8789-512 (N.P.)

Abstract: Advances in the regenerative stem cell field have propelled the generation of tissue-specific cells in the culture dish for subsequent transplantation, drug screening purposes, or the elucidation of disease mechanisms. One major obstacle is the heterogeneity of these cultures, in which the tissue-specific cells of interest usually represent only a fraction of all generated cells. Direct identification of the cells of interest and the ability to specifically isolate these cells in vitro is, thus, highly desirable for these applications. The type VI intermediate filament protein NESTIN is widely used as a marker for neural stem/progenitor cells (NSCs/NPCs) in the developing and adult central and peripheral nervous systems. Applying CRISPR-Cas9 technology, we have introduced a red fluorescent reporter (mScarlet) into the NESTIN (NES) locus of a human induced pluripotent stem cell (hiPSC) line. We describe the generation and characterization of NES-mScarlet reporter hiPSCs and demonstrate that this line is an accurate reporter of NSCs/NPCs during their directed differentiation into human midbrain dopaminergic (mDA) neurons. Furthermore, NES-mScarlet hiPSCs can be used for direct identification during live cell imaging and for flow cytometric analysis and sorting of red fluorescent NSCs/NPCs in this paradigm.

Keywords: iPSC; NESTIN; reporter; CRISPR-Cas9; neural stem cells; midbrain dopamine neurons

1. Introduction

Human induced pluripotent stem cell (hiPSC) lines are derived from somatic cells by reprogramming and serve as an invaluable resource for studying human cell and tissue models in vitro. The hiPSCs enable research about the mechanisms of differentiation in early human development, the physiology of specific lineages in 2D cultures and of cellular interactions in 3D organoids [1,2]. Since hiPSC lines can be established from cohorts of patients and healthy donors, they are also excellent tools for deciphering disease mechanisms and the screening of new drugs in vitro [3,4]. Moreover, hiPSC-derived precursor and differentiated cells have the potential for cell replacement therapies to cure a variety of degenerative diseases affecting different organs, including the central nervous system (CNS) [5].

Parkinson’s Disease (PD), which is characterized by the inexorable degeneration of a particular type of dopamine (DA)-producing neurons in the human brain and is typically diagnosed only at an advanced stage of the disease, has received particular attention in the regenerative medicine field [6]. The loss of the midbrain dopaminergic (mDA) neurons, especially those of the substantia nigra pars compacta (SNC), leads to the typical
motor symptoms of PD, including the inability to execute voluntary movements, tremor
and rigidity [7]. Replacement of the degenerating mDA neurons by fetal-brain-derived
mDA precursor cells, which are transplanted into the brains of PD patients, is capable of
restituting the DA levels required for their appropriate motor function. This approach is
considered a promising alternative to the current practice of pharmacotherapy or deep
brain stimulation for the symptomatic treatment of this disease [6]. The restricted availabil-
ity and ethical dispute of fetal-brain-derived cells has propelled the use of stem cell-derived
mDA precursors in recent years, leading to several ongoing clinical trials [6]. The mDA
precursors are generated from human pluripotent stem cells (PSCs) subjected to a strict
sequence of defined media and soluble factor treatments in the culture dish, commonly
seen as the directed differentiation of these cells [8]. However, high quality standards need
to be applied for the derivation of these precursors from a PSC pool, including thorough
assessment of their identity and purity [9]. The mDA lineage is characterized by the stage-
and cell-type-specific expression of several transcription factors, such as forkhead box A2
(FOXA2), orthodenticle homeobox 2 (OTX2), engrailed homeobox 1 (EN1) and LIM home-
obox transcription factor 1 alpha (LMX1A) in proliferating mDA neural stem/progenitor
cells (NSCs/NPCs) and postmitotic precursors; whereas the paired-like homeodomain 3
(PITX3) transcription factor, the rate-limiting enzyme in DA synthesis tyrosine hydroxy-
lyase (TH) and the DA transporter (DAT/SLC6A3) are detected only in maturing mDA
neurons [10–12]. Additional marker proteins are used to distinguish between the SNc DA
neuron subset, preferentially expressing the aldehyde dehydrogenase 1 family member
A1 (ALDH1A1) and dopamine receptor D2 (DRD2), and the ventral tegmental area (VTA)
DA neuron subset, expressing the calcium (Ca²⁺) binding protein calbindin 1 (CALB1)
and cholecystokinin (CCK) [10,12]. Furthermore, the absence of “classical” pluripotency
markers, such as POU class 5 homeobox 1 (POU5F1/OCT4), SRY-box transcription factor 2
(SOX2) and Nanog homeobox (NANOG), and markers characteristic of other brain regions,
including the forebrain gene forkhead box G1 (FOXG1), the diencephalic genes BarH-like
homeobox 1 (BARHL1) and paired box 6 (PAX6) as well as the hindbrain gene homeobox
A2 (HOXA2), is a necessary requirement for the use of the generated mDA precursors as
cell replacements of the degenerating mDA neurons [9,13]. Such criteria ensure the low
tumorigenicity and proper functional integration of the transplanted cells into the circuitry
of the diseased brain. They also make the isolation and purification of the target cell type
(e.g., mDA precursors) a highly desirable but critical endeavor in the regenerative stem
cell field, given the still-remarkable heterogeneity of the generated cells in current PSC
differentiation paradigms [6,9].

The type VI intermediate filament NESTIN is expressed in proliferating stem and
progenitor cells from different tissues, including NSCs and NPCs of the CNS and peripheral
nervous system, bone marrow mesenchymal and hematopoietic stem cells, hair follicle
stem cells, developing myotomes, skeletal muscle satellite cells and pancreatic islet stem
cells [14]. NESTIN expression is downregulated, whereas other cytoskeletal proteins, such
as the class III beta-tubulin (TUBB3) in the neural lineage, are upregulated, as soon as these
stem/progenitor cells differentiate into more committed cells [14–16]. NESTIN is, thus,
used as an NSC/NPC-specific marker protein in the context of human neural differentiation.
Indeed, green fluorescent reporter PSCs for this cell population have been generated using
either the endogenous NESTIN (NES) locus or the regulatory regions located in the second
intron of this gene to direct the expression of the transgene specific to NSCs/NPCs [17,18].

Here we report the generation and characterization of reporter hiPSC lines expressing
the red fluorescent protein (RFP) mScarlet under the direct control of the NES locus. Using
CRISPR-Cas9 technology, we targeted the C-terminus of NESTIN and inserted the mScarlet
coding region, together with a self-cleaving 2A peptide sequence, immediately upstream
of the stop codon. Through independent translation of the reporter and avoidance of a
selection marker, perturbation of the targeted locus was minimal and ensured the faithful
expression and function of both the NESTIN and mScarlet reporter proteins. Using a
modified protocol for the directed differentiation into mDA neurons, we show that the
new NES-mScarlet reporter hiPSC line is particularly valuable for the direct observation of NESTIN-positive human NSCs/NPCs in live cell imaging and flow cytometric analyses, including downstream applications upon cell sorting. The red color reporter is of particular utility when combined with probes requiring additional green fluorescence, such as indicators for Ca$^{2+}$ imaging. The NES-mScarlet reporter hiPSC line could be useful for the generation of other tissue and cell types under the appropriate conditions and might support clinical applications for the screening of new drugs and cell replacement therapy beyond mere research.

2. Materials and Methods

2.1. hiPSC Cell Culture for Gene Targeting

Human XM001 iPSCs (https://hpscreg.eu (accessed on 11 January 2021), HMGU-001-A) [19] were derived from fibroblasts of a healthy female and were obtained from Heiko Lickert (Helmholtz Center Munich, Munich, Germany). XM001 hiPSCs were grown in Essential 8 Flex Medium (E8; Thermo Fisher Scientific, Waltham, MA, USA) on Vitronectin-coated (5 µg/mL) dishes and passaged every 2 to 3 days using DPBS (w/o Ca, Mg, Thermo Fisher Scientific/0.5 mM EDTA or Accutase (#A1110501; Thermo Fisher Scientific) for dissociation, followed by overnight incubation in E8 medium with ROCK inhibitor (Y27632, 10 µM/mL; Tebu-Bio, Offenbach, Germany). Subclones were frozen in Bambanker freezing medium (Nippon Genetics Europe, Düren, Germany) or E8/10% DMSO and stored in liquid nitrogen. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the Ärztekammer Westfalen-Lippe and Westfälische Wilhelms Universität Münster (protocol code 2019-426-f-S on 17 September 2019).

2.2. Targeting of the Human NESTIN Locus

XM001 hiPSCs were transfected with a plasmid for the expression of Cas9, RFP ([20], Addgene ID 86987), a cloned sgRNA targeting the end of NES exon 4 (CTGGTCCTCAGGGGAGGACT), a plasmid for the expression of BCL-XL to reduce apoptosis [21] and the NES-targeting vector at equal ratios using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA). The targeting vector (plasmid backbone pMA, manufactured by Thermo Fisher Scientific) comprised 1.5 kb of sequences located upstream and downstream of the NES stop codon with the in-frame insertion of a P2A peptide, preceded by a Furin cleavage site (RAKR) [22], and followed by the mScarlet coding sequence [23] upstream of the stop codon (see Appendix A). Transfected RFP+ cells were enriched by fluorescence-activated cell sorting, replated, expanded and subjected to a second cycle of transfection and cell sorting to increase the overall targeting efficiency. Sorted cells were plated at low density and single-cell-derived colonies were isolated after 2 to 3 weeks, expanded, frozen and used for the isolation of genomic DNA.

2.3. PCR Genotyping

Genotyping was performed by PCR on genomic DNA from transfected hiPSC clones using primer pairs P1/2, P3/4, P5/6 or P7/8 (Figure 1, Table 1) and Q5 (New England Biolabs, Ipswich, MA, USA) or Herculase II (Agilent, Santa Clara, CA, USA) DNA Polymerase at 63–65 °C annealing temperature. PCR reactions were analyzed by agarose gel electrophoresis. For Sanger sequencing, PCR bands were isolated using the GeneJET Gel Extraction Kit (Thermo Fisher Scientific), sequenced by LGC Genomics GmbH (Berlin, Germany) and analyzed using the CLC Main workbench software (Qiagen Digital Insights, Aarhus, Denmark).
**Figure 1.** Insertion of mScarlet into the NES locus of human iPS cells (hiPSCs). The wildtype NES locus was cut with Cas9 and sgRNA spanning the stop codon at the end of exon 4. The targeted double-strand break could be repaired by homologous recombination with a targeting vector that included the in-frame insertion of a 2A peptide and the mScarlet coding sequence, flanked by 5′ and 3′ homology regions (5HA, 3HA). Upon the activation of the genomic locus, mScarlet was co-translated with NESTIN via the 2A peptide. The position of PCR primers, product sizes and a size scale are indicated.

**Table 1.** Primers used for genotyping.

| Name | Sequence (5′–3′)                        |
|------|----------------------------------------|
| P1   | GTGGGATGGAGGATGCAGGC                   |
| P2   | GCTCCTTTGCCACACCCCTT                   |
| P3   | GAGTTCATGCGGTTCAAGGTGC                 |
| P4   | CCAGCCCATTGTCTTCTTCTTCTG              |
| P5   | CAGGCCATCTGACCGGAAAGA                 |
| P6   | GCACCTTGAACCGCATGAACCT                 |
| P7   | GGGATTGACTCCAAAACGAGGAGC              |
| P8   | GCAGAAGAAGACATGGGACTTG                |

**2.4. Karyotype Analysis**

hiPSCs were karyotyped with genomic DNA for SNP analysis using the Illumina OMNI-EXPRESS-8v1.6 Chip (Illumina, San Diego, CA, USA) (coverage of 958,497 markers spanning the human genome) and results were read with an Illumina iSCAN array scanner. Results were analyzed using Karyostudio 1.3 software, based on the information of the GRCh36/hg18 dataset. This method detects genomic gains and losses, copy number variants (CNVs), duplications/deletions, unbalanced translocations, aneuploidies, copy neutral aberrations and loss of heterozygosity/absence of heterozygosity.
2.5. Off-Target Site Prediction and Analysis

The sgRNA (CTGGTCCTCAGGGGAGGACT) on-target site and off-target sites were predicted using the CRISPOR webtool [24]. The off-target sites were analyzed as described in Figure S3.

2.6. Directed Differentiation of hiPSCs into mDA Neurons

Wildtype (wt) XM001 and NES-mScarlet hiPSCs (passage number 28) were maintained on hESC-qualified Matrigel (#354277; Corning, Amsterdam, The Netherlands)-coated plates in StemMACS™ iPS-Brew medium (#130-104-368; Miltenyi Biotec, Bergisch Gladbach, Germany). The pluripotency of hiPSC lines (quality control (QC) No. 1) was confirmed by quantitative RT-PCR (RT-qPCR) and ICC for pluripotency marker genes (Table 2) and proteins (Human Embryonic Stem Cell Marker Panel#ab238602; Abcam, Boston, MA, USA). Directed differentiation of the hiPSCs into mDA neurons was conducted in a monolayer culture using a modified protocol from [13,25,26], as follows. The hiPSCs were dissociated in 0.5 mM EDTA/DPBS (w/o Ca, Mg) and plated onto Matrigel (#356234; Corning) and 0.5 µg/cm² of human recombinant laminin 111 (#LN111; BioLamina, Sundbyberg, Sweden)-coated tissue culture plastic at a density of 0.5–1.5 × 10⁴ cells/cm² in N2 medium (1:1 mixture of DMEM:F12 (#21331020; Thermo Fisher Scientific) and Neurobasal (#21103049; Thermo Fisher Scientific), 1% N-2 supplement (#17502001; Thermo Fisher Scientific), 1% GlutaMAX (#35050038; Thermo Fisher Scientific) and 0.2% penicillin/streptomycin(#15140-122; Thermo Fisher Scientific)) with 1% RevitaCell™ Supplement (#A2644501; Thermo Fisher Scientific) for 24 h. Cells were kept in N2 medium for the next 10 days (d) of differentiation (d10) and 100 ng/mL of human Noggin(#130-103-456; Miltenyi Biotec), 10 µM of SB431542 (#130-106-543; Miltenyi Biotec) BMP/TGFβ inhibitors and 375 ng/mL of active human SHH (C24II) (#130-095-727; Miltenyi Biotec) were added from d0 to d9 (SB431542) or d10 (Noggin and SHH C24II) to this medium. Cells were treated with 100 ng/mL of human FGF8b (#130-095-740; Miltenyi Biotec) from d2, and 0.6 µM CHIR99021 (#130-106-539; Miltenyi Biotec) from d3 to d16 of this differentiation protocol. Cells were split using 0.5 mM EDTA/DPBS (w/o Ca, Mg) between d9 to d11 and cryopreserved at −150 °C in freezing medium (1:1 mixture of DMEM:F12 and Neurobasal, 1% N-2 supplement, 4% B-27 supplement without vitamin A (#12587001; Thermo Fisher Scientific) and 1% GlutaMAX, 10% DMSO) on d16 of their differentiation [15]. After passing or thawing, pre-patterned ventral midbrain (VM)/mDA NSCs/NPCs were plated at a density of 2.6 × 10³ cells/cm² in B27 medium (Neurobasal, 2% B-27 supplement without vitamin A, 1% GlutaMAX and 0.2% penicillin/streptomycin) with 1% RevitaCell™ Supplement (for 24 h) and supplemented with 20 ng/mL of human BDNF (#130-096-286; Miltenyi Biotec) and 0.2 mM L-ascorbic acid (#A4403; Sigma-Aldrich, Taufkirchen, Germany) from d10, and with 10 ng/mL of human GDNF (#212-GD-010; R&D Systems, Minneapolis, MN, USA), 500 µM dibutyryl-cyclic AMP (db-cAMP) (#D0627; Sigma-Aldrich) and 1 µM N-[3,5-difluorophenyl]acetyl]-l-alanyl-2-phenylglycine-1, 1-dimethylylethyl ester (DAPT) (#2634; Bio-Techne, Wiesbaden-Nordenstadt, Germany) from d16 for the remaining culture time. Composition of each medium is summarized in Appendix B. At d31 (QC No. 2) and d61 (QC No. 3) of this modified differentiation protocol, the pre-patterned VM/mDA NSCs/NPCs and differentiating mDA precursors and neurons were routinely tested by RT-qPCR for the expression of stage-, region- or neuronal cell-type-specific marker genes (Table 2).
Table 2. Marker-gene-specific primer and amplicon sizes for RT-qPCR.

| Marker Gene (Stage/Region/Type) | Forward Primer (5′–3′) | Reverse Primer (5′–3′) | Tm (°C) | Product Size (bp) |
|---------------------------------|-------------------------|-------------------------|---------|-------------------|
| ACTB (housekeeping gene)       | GCACAGAGCCTCGGCTT       | CCTTGACATGGCCGGAG       | 59.68   | 112               |
| ALDH1A1 (SNc DA neurons)       | ATCAAAAGAGCTGCGGGA      | GCATTTGCTCAAGTGGCATC    | 59.96   | 113               |
| BARHL1 (forebrain)             | GTACGAGACGAGGACTAAA     | AGAAATAAGCCAGGACGGAACAT | 60.03   | 60.09             |
| CALB1 (VTA DA neurons)         | ACGCAGCTGTGAGCTTATTCT  | CAGAGGCCTGACCAGCCATATTA| 60.53   | 60.69             |
| CCK (VTA DA neurons)           | AAGTGACCGGGACTACAGA     | GTTCGTTCTGCAAGTGGTATCC | 59.10   | 119               |
| DDC (mDA neurons)              | ACTACAGGAGACGAGGACTAAA | AGGAGGCCTGACCAGGCAAGAT | 60.32   | 60.25             |
| EN1 (VM/mDA NPCs)              | CGTGCCTATCCCACTCTTGA   | TCCTGCCGTTCTCTCCCTTC   | 57.30   | 60.11             |
| FOXA2 (VM/mDA NPCs)            | CCGTTCTCCAAACCAACACT   | TGGGTTAGGACATTTCAAGGA  | 57.81   | 59.67             |
| HOXA2 (hindbrain)              | CCGGCTCGTTCTGAGTTGCTA  | TGGTATTCTCTCCCTCCTCC   | 66.25   | 77                |
| LMX1A (mDA NPCs)               | CGATCATCATATTTTACTCTCT | TGGTATTCTCTCCCTCCCTCT | 57.71   | 60.32             |
| NANO (pluripotency)            | TGAACCTGACAATTCTAAGG   | TGGGCTGAAAGAGTAAAGA    | 55.32   | 60.53             |
| NES (NSCs)                     | GCCTGCAAGAGGATGTTGAGA  | TGGGACGAAAGAGTCCACAGC  | 60.53   | 57.30             |
| NES-mScarlet (bicistronic mRNA)| GCTCCTAAAGCTCTACAGAGGG | CTCGCCCTGATCTGAAATCG   | 60.56   | 60.44             |
| OTX2 (VM/mDA NPCs)             | ACCAACTCCTATCTCAAGA    | TGGGACGACAGGCCGCTGTTA  | 58.38   | 58.43             |
| PAX6 (forebrain, neural rosettes) | CTTGGTCTCCTCTCTCTCTCT | CTTGGTCTCCTCTCTCTCTCT | 66.71   | 65.02             |
| PITX3 (mDA neurons)            | AGAGGAGGCTTGCGCTGAAAAA | TTCCCTCTCTGAGAGATGCT  | 60.20   | 61.26             |
| POLI5F1 (pluripotency)         | ACGAGAGGCTTGCGCTGAAAAA | TTCCCTCTCTGAGAGATGCT  | 57.44   | 60.19             |
| mScarlet (reporter)            | GACATGCACCCTCCCCACACAGA| TGTGATAGTCGCTCCGATG    | 59.68   | 60.39             |
| SLC6A3 (DAT) (mDA neurons)     | CAAATGCTTGGGTCAGAACT   | CACTCCCTCCTGTCCCTCCTTCT| 60.32   | 60.68             |
| SOX2 (pluripotency + NSCs)     | ATGGGCTGCTGCTGCTGCTGCTCTTTG | 59.96   | 60.78             |
| TH (mDA neurons)               | GACACCCTCCACTGAGCAGAT | ATGATGGGCTCCTGCTGCTT  | 61.56   | 61.93             |
| TUBB3 (neurons)                | TTCTCGACAGTACAGGCTCG  | GAAAGATGTCCAAAGGACC   | 60.34   | 60.68             |
2.7. Reverse Transcription and Quantitative Polymerase Chain Reaction (RT-qPCR)

Cells at the corresponding stages in 6-well plates were harvested by treatment with 0.5 mM EDTA/DPBS (w/o Ca, Mg; only hiPSCs) or Accutase for ~5 min and pelleting at 350 × g for 4 min. Total RNA was isolated with the Monarch Total RNA Miniprep Kit (#T2010S; New England Biolabs) and 1 µg of total RNA was reverse transcribed using LunaScript® RT SuperMix Kit (#M3010L; New England Biolabs), following the manufacturers’ instructions. PCR reactions were set up in duplicates in 96-well plates or 0.2 mL tubes using 1 µL of cDNA, 1 µM of the primer pairs listed in Table 2 (biomers.net GmbH, Ulm, Germany) and PowerUp™ SYBR™ Green Master Mix (#A25742; Thermo Fisher Scientific). Amplifications were performed on a StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific) with the following parameters: 30 s at 95 °C, 1 min at 60 °C for 40 cycles. Normalized ratios for each gene of interest were calculated by the formula $2^{-\Delta \Delta Ct}$, and normalized fold changes (relative to undifferentiated hiPSCs) were calculated by the $2^{-\Delta \Delta Ct}$ method, in which ΔCt is the Ct value of the gene of interest minus the Ct value of the housekeeping gene ACTB (internal control) [27]. Data are from three technical replicates (independent differentiation experiments) [28].

2.8. Immunocytochemistry (ICC)

Cells were grown on 4-, 8- or 18-well μ-slides (ibidi, Gräfelfing, Germany) to the corresponding stages, rinsed twice in PBS pH 7.4 and fixed in 4% paraformaldehyde in PBS for 15 min, washed 3x in PBS for 5 min, permeabilized in 0.5% Triton X-100/PBS for 15 min and washed 3x in PBS for 5 min, all at room temperature. Cells were pre-incubated in 5% normal donkey serum (NDS) in permeabilization solution for 1 h at room temperature and incubated with primary antibodies (Table 3) overnight at 4 °C. After 3 × 10 min washes in PBS, cells were incubated with Alexa Fluor 488 and 555 secondary antibodies (Table 4) in 2.5% NDS in permeabilization solution for 1–2 h, washed 3 × 10 min with TBS (50 mM Tris-HCl pH 7.5; 0.9% NaCl) and incubated with 0.5 µg/mL of 4′,6-diamidino-2-phenylindole (DAPI) in PBS for 15 min, all at room temperature. After 3 × 5 min washes in TBS, cells were mounted in mounting medium (ibidi) and imaged on a DMI8 widefield microscope (Leica Microsystems, Wetzlar, Germany). Images were acquired with a DFC9000 GT sCMOS camera using LAS X Premium software (Leica Microsystems) and processed with Adobe Photoshop (Adobe, San Jose, CA, USA) software.

Table 3. Primary antibodies for ICC and WB.

| Antibody (Species) | Dilution | Catalogue Nr. | Manufacturer |
|--------------------|----------|---------------|--------------|
| β-Actin (Mouse)    | 1:5000   | 60008         | proteintech 1 |
| CALB1 (Rabbit)     | 1:2000   | CB38          | Swant        |
| EN1 (Mouse)        | 1:100    | 4G11          | DSHB 2       |
| LMX1 (Rabbit)      | 1:1000   | AB10533       | Merck Millipore |
| NANO2 (Rabbit)     | 1:500    | ab21624       | abcam        |
| NESTIN (Rabbit)    | 1:500    | ABD69         | Merck Millipore |
| OTX2 (Goat)        | 1:2000   | AF1979        | R&D Systems  |
| OCT4 (POU5F1) (Rabbit) | 2 µg/mL | ab19857       | abcam        |
| RFP (Mouse)        | 1:500    | 409 011       | Synaptic Systems |
| RFP (Mouse)        | 1:1000   | 6g6           | Chromotek 1   |
| SOX2 (Rabbit)      | 1:250    | ab97959       | abcam        |
| TRA-1-60 (Mouse)   | 1:500    | ab16288       | abcam        |
| TH (Mouse)         | 1:1000   | MAB318        | Merck Millipore |
| TH (Rabbit)        | 1:1000   | AB152         | Merck Millipore |
| TUBB3 (Mouse)      | 1:1000   | 801213        | BioLegend     |

1 For WB. 2 Developmental Studies Hybridoma Bank, University of Iowa, USA.
Table 4. Secondary antibodies for ICC and WB.

| Antibody                        | Dilution | Cat. Nr.   |
|---------------------------------|----------|------------|
| Donkey anti-Mouse IgG Alexa Fluor Plus 488 | 1:1500   | A32766     |
| Donkey anti-Mouse IgG Alexa Fluor Plus 555 | 1:1500   | A32773     |
| Donkey anti-Rabbit IgG Alexa Fluor Plus 488 | 1:1500   | A32790     |
| Donkey anti-Rabbit IgG Alexa Fluor Plus 555 | 1:1500   | A32794     |
| Donkey anti-Goat IgG Alexa Fluor Plus 555 | 1:1500   | A32816     |
| Goat anti-Mouse IgG HRPO        | 1:4000   | SBA-1031-05 |
| Goat anti-Rabbit IgG HRPO       | 1:10000  | ab6721     |

1 Invitrogen/Thermo Fisher Scientific, for ICC. 2 Biozol (Eching, Germany), for WB. 3 abcam, for WB.

2.9. Cell Counting

Immunostained cells grown on 4-, 8- or 18-well µ-slides (ibidi) were visualized with a DMI8 (Leica Microsystems) widefield microscope equipped with brightfield, phase-contrast and fluorescence optics. Images were acquired with a DFC9000 GT sCMOS camera using LAS X Premium software (Leica Microsystems). For each well, three random fields were selected and photographed. Single-positive cells immunostained for TH, TUBB3, NESTIN and RFP (mScarlet), and counterstained with DAPI, were manually counted in each of these fields. Subsequently, the numbers of double-positive cells for the corresponding marker proteins were determined by the overlay images for each field. Cell numbers were averaged, and the percentage of TH-single-positive or TH- and TUBB3-double-positive cells among all DAPI+ or TUBB3+ cells, respectively, or the percentage of NESTIN and/or RFP single- and double-positive cells among all marker-positive cells was calculated and subjected to statistical analyses.

2.10. Enzyme-Linked Immunosorbent Assay (ELISA) for Catecholamines

Cells grown in 6-well plates at d51 of the modified differentiation protocol were treated as described by Kim et al. [29]. Briefly, cells were incubated in fresh B27 medium alone for 30 min and sequentially exposed to DPBS (w/o Ca, Mg) (basal condition) and modified Tyrode's solution (119 mM NaCl, 2 mM CaCl2, 1.2 mM MgCl2·6 H2O, 10 mM glucose, 3.3 mM HEPES and 2.7 mM HEPES-Na+ salt; pH 7.4) with low (3 mM) and high (40 mM) potassium chloride (KCl) for 10 min each at 37 °C. Supernatants were collected and immediately mixed with 1 mM ascorbic acid and 1 mM EDTA to prevent DA auto-oxidation. Cells were detached with Accutase and lysed in lysis buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris, pH 8.0 and Halt™ Protease Inhibitor Cocktail (#78786; ThermoFisher Scientific)) to determine their total protein content by Bradford assay (#K015.1; Roth, Karlsruhe, Germany). Catecholamine (DA, noradrenaline and adrenaline) contents in the supernatants were determined using a TriCat ELISA (#RE59395; IBL International/Tecan, Hamburg, Germany) and an Emax Plus microplate reader (Molecular Devices, San Jose, CA, USA), according to the manufacturers’ protocols. The catecholamine contents were normalized to the total protein content in each sample.

2.11. Western Blot (WB)

Cells grown in 6-well plates from d7 to d61 of the modified differentiation protocol were lysed in lysis buffer (see Section 2.10) and boiled in 2× Laemmli buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 25% glycerin, 0.01% bromophenol blue and 5% β-mercaptoethanol) at 95 °C for 5 min. Total proteins (1 µg per sample, determined by Bradford assay) were separated by 10% SDS-PAGE, blotted on Amersham™ Protran® nitrocellulose membranes (#GE10600001; Sigma-Aldrich) and stripped, as described by [30]. Blots were probed with the primary antibodies and horseradish peroxidase (HRPO)-conjugated secondary antibodies listed in Tables 3 and 4, respectively, developed in Pierce™ ECL Substrate (#32209; ThermoFisher Scientific) and imaged with a ChemiDoc Touch Imaging System (Bio-Rad Laboratories, Hercules, CA, USA).
2.12. Live Cell and Ca\(^{2+}\) Imaging

Cells grown in 6-well plates were directly visualized with a DMi8 widefield microscope (Leica Microsystems). Phase-contrast and fluorescent images were acquired with a DFC9000 GT sCMOS camera using LAS X Premium software (Leica Microsystems). For Ca\(^{2+}\) imaging, cells were grown in 35 mm µ-dishes (ibidi) until the desired stage. Before imaging, cells were rinsed once with recording medium (128 mM NaCl, 1 mM CaCl\(_2\), 1 mM MgCl\(_2\), 45 mM sucrose, 10 mM glucose and 10 mM HEPES; pH 7.4) and incubated in this medium with 4 µg/mL of Fluo-8-AM for 30 min at 37 °C, as described by Carola et al. [31]. Cells were washed once with recording medium to remove residual Fluo-8, replenished with fresh recording medium and immediately imaged on a DMi8 widefield microscope equipped with an on-stage incubator (Pecon/Leica Microsystems).

2.13. Flow Cytometry and Fluorescence-Activated Cell Sorting

Pre-patterned wt (XM001) and NES-mScarlet VM/mDA NSCs/NPCs grown in 6-well dishes at d11 and d23 of the modified differentiation protocol were harvested and dissociated in Accutase to obtain a single-cell suspension. Cells were resuspended in 2% human serum albumin (#9988; Irvine Scientific, Santa Ana, CA, USA) in DPBS (w/o Ca, Mg). Flow cytometry and fluorescence-activated cell sorting of mScarlet\(^{+}\) cells were performed with a BD FACSMelody\(^{TM}\) Cell Sorter (BD Biosciences, Franklin Lakes, NJ, USA). The population of interest was identified through gating for singlets and cell size and granularity, based on the forward and side scatter of the wt control. A total of 30,000 events were acquired for each sample. Data were plotted with FlowJo\(^{TM}\) software (LLC/BD Biosciences).

2.14. Statistical Analysis

Data are represented as the mean ± SEM from three or two independent experiments (technical replicates, [28]) for RT-qPCR and cell counting or ELISA, respectively. For statistical calculations, graphs were plotted and a two-sample t-test was conducted with a significance threshold of 95% (* \(p < 0.05\)) or 99.5% (** \(p < 0.005\)) using MATLAB software version R2021b. Non-significant results were not labelled in the graphs.

3. Results

3.1. Generation of NES-mScarlet Reporter hiPSCs

For the targeting of the human NESTIN (NES) gene, we constructed a recombination vector comprising a 2A self-cleaving peptide [22] and the mScarlet coding region [23] flanked by 1.5 kb homology regions located up- and downstream of the NES stop codon in exon 4 (Figure 1). Upon induction of a double-strand break in the NES locus of hiPSCs using Cas9 and a sgRNA recognizing the end of exon 4, the P2A-mScarlet coding region was inserted by homologous recombination upstream of the NES stop codon. The targeting vector was transfected into the XM001 hiPSCs, together with an expression vector for Cas9, sgRNA and RFP. Three days later, the transfected cells were enriched by fluorescent cell sorting, replated, subjected to a second cycle of transfection/sorting to increase the overall targeting efficiency and plated at low density for the isolation of single-cell-derived colonies. Isolated hiPSC colonies were further expanded and genomic DNA was analyzed by PCR for the detection of wildtype or targeted NES alleles. We characterized 24 colonies initially with primer pair P1/P2 able to detect the wildtype NES allele by a 474 bp band and genomic vector copies by a 1254 bp band (Figure 1).

Six of the tested clones exhibited the vector-specific band, either together with the wildtype band (clones #8 and #23) or did not exhibit the wildtype band (clones #7, #16, #18 and #21), suggesting that both NES alleles were targeted in the latter group (Figure 2). For the further genotyping of these clones, we designed primers P5/P6 and P7/P8 for amplification of the targeted loci using an mScarlet primer binding site located within the vector and a genomic primer outside of the vector homology regions. This analysis revealed that all of the 6 clones exhibited the 1659 bp band predicted from the upstream
region of the targeted NES locus (P5/P6, Figure 1) and 5 clones (except for clone #8) showed the predicted 1855 bp band covering its downstream region (P7/P8, Figure 1) (Figure S1). PCR products were Sanger-sequenced and compared to the sequence of the targeted NES locus upon recombination with the NES-mScarlet targeting vector. This analysis confirmed the presence of correctly targeted alleles in clones #7, #18, #21 and #23. Due to the absence of the NES wildtype band, clones #7, #18 and #21 were homozgyously targeted, whereas clone #23 harbored one targeted and one wildtype allele. Karyotyping using an Illumina platform for SNP analysis confirmed normal karyotypes for clones #18, #21 and #23, whereas clone #7 showed a duplication on chromosome 1 and was excluded from further analysis (Figure S2). In the remaining three clones (#18, #21 and #23), the set of six predicted off-target sites showing one or two mismatches to the sgRNA target sequence were analyzed and confirmed to be unaltered (Figure S3).

### Figure 2

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | + | - | M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| -1500 bp | -1000 bp | -750 bp | -500 bp | -250 bp |

PCR genotyping of NES-mScarlet hiPSC clones using primer pair P1/P2. Genomic DNA from 24 XM001 hiPSC clones derived from transfection with Cas9/sgRNA and a NES-targeting vector was subjected to PCR amplification using primers P1/P2. The wildtype NES locus yielded a band of 474 bp, whereas a 1254 bp band was amplified from the targeting vector in clones #7, #8, #16, #18, #21 and #23. +, untransfected control DNA; −, water control; M, size marker.

### 3.2. NES-mScarlet hiPSCs Retain Expression of Pluripotency Marker Genes

After the initial expansion of the three correctly targeted NES-mScarlet hiPSC clones #18, #21 and #23, we further characterized these cells based on their morphology, growth, pluripotency and reporter expression. Because we did not detect the red mScarlet reporter by direct visual inspection under a fluorescence microscope in the heterozygote clone #23, we discarded this hiPSC clone from further analyses (see also Section 3.5). The better growth properties of NES-mScarlet hiPSC clone #18 (henceforth named NES-mScarlet #18) compared to clone #21 (both homozygous for the targeted locus; data not shown) let us characterize clone #18 in more depth. To determine whether the CRISPR-Cas9-targeted and expanded (passage 31) NES-mScarlet hiPSCs retained their pluripotent properties, the expression of the pluripotency genes POU5F1 (OCT4), SOX2 and NANOG was determined in these cells by RT-qPCR (QC No. 1) and ICC. Transcription of POU5F1 (OCT4), SOX2 and NANOG in the NES-mScarlet #18 hiPSCs was comparable to the parental XM001 wt hiPSCs, and no statistically significant difference was detected between these two cell lines (Figure 3a). Moreover, the corresponding proteins POU5F1 (OCT4), NANOG and SOX2, as well as the additional human-specific and cell surface marker TRA-1-60, were expressed in all targeted cells to a similar extent as in the wt hiPSCs (Figure 3b). We thus concluded that the newly generated NES-mScarlet hiPSCs (clone #18) retained their normal growth characteristics and pluripotent properties.
The mRNA levels of the ventral marker FOXA2. To this end, we modified the previously published monolayer protocols [13,25,26] by

Figure 3. CRISPR-Cas9-targeted NES-mScarlet hiPSCs retain their pluripotency. (a) RT-qPCR for the pluripotency marker genes POU5F1 (OCT4), SOX2 and NANOG on total RNA isolated from *wt* (XM001) or NES-mScarlet #18 hiPSCs. The values shown are the $2^{-\Delta \text{Ct}}$ ratios of the difference between cycle thresholds (dCt) of the corresponding marker genes and the housekeeping gene ACTB; $n = 3$ independent differentiation experiments; (b) ICC for the detection of the pluripotency marker proteins POU5F1 (OCT4), SOX2, NANOG and TRA-1-60 in the NES-mScarlet #18 and *wt* hiPSCs. Top panels are the single green (POU4F1 and NANOG) or red (SOX2 and TRA-1-60) and blue (DAPI) channel views of the merged images below. Scale bars: 100 µm.

3.3. NES-mScarlet hiPSCs Differentiate into Ventral Midbrain Human Neural Stem and Progenitor Cells

To determine their ability to generate human NSCs/NPCs and their potential as reporter cells for this cell type and stage, we differentiated the targeted NES-mScarlet hiPSCs under defined conditions into NSCs/NPCs of a specific brain region, the VM. To this end, we modified the previously published monolayer protocols [13,25,26] by monitoring the expression of specific marker genes for VM NSCs/NPCs (Table 2) in the differentiating cells (Figure 4a). The simultaneous differentiation of the parental *wt* (XM001) hiPSC line under the same conditions was used as a control. The identity of the generated NSCs/NPCs was determined through the detection of these genes and proteins by RT-qPCR and ICC on d31 of the modified differentiation protocol, after passaging and, eventually, cryopreservation of the cells (QC No. 2; Figure 4a). The transcription of the VM marker genes FOXA2, LMX1A, OTX2 and EN1 was robustly induced in the NES-mScarlet #18-derived cells, similar to their *wt* counterparts, at d31 of the modified protocol (Figure 4b). The mRNA levels of the ventral marker FOXA2 were significantly lower ($p = 0.0456$), and the transcription of the midbrain marker EN1 was significantly higher ($p = 0.0008$), in the NES-mScarlet #18-derived cells compared to their *wt* counterparts, whereas OTX2 and the VM- and mDA-specific marker gene LMX1A did not show any significant differences between both hiPSC lines.
NES-mScarlet #18 and wt NSCs/NPCs, these cells exhibited much lower mRNA ratios of the forebrain marker FOXG1, the diencephalic marker BARHL1 and the hindbrain marker HOXA2 compared to the midbrain markers EN1 and OTX2 (Figure 4c). The transcription of the ventral diencephalic marker BARHL1 was significantly higher ($p = 0.016$) in the NES-mScarlet #18 cells compared to the wt cells.

To confirm their identity as VM NSCs/NPCs, we assessed the expression of the NSC marker proteins NESTIN and SOX2, alone or together with the midbrain markers EN1, OTX2 and the VM and mDA-specific marker LMX1, by ICC on the differentiating cells (Figures 4d and S4). NESTIN and SOX2 were expressed in almost all NES-mScarlet #18-derived cells, and NESTIN co-localized with EN1 or OTX2 in most cell nuclei at d31 of the modified differentiation protocol (Figures 4d and S4). The expression of the VM and mDA-specific marker LMX1, by contrast, was restricted to a subset of the differentiating cells at this stage of the protocol, consistent with the lower LMX1A mRNA ratios in these cultures (Figures 4b,d and S4). We concluded that despite some variabilities in the mRNA levels of certain brain-region- and cell-type-specific marker genes between the NES-mScarlet #18-derived NSCs/NPCs and their wt counterparts, the generated NES-mScarlet hiPSCs (clone #18) are capable of differentiating under defined culture conditions into bona fide NSCs/NPCs with a VM identity.

**Figure 4.** NES-mScarlet hiPSCs differentiate into genuine VM NSCs/NPCs. (a) Schematic depiction of the modified differentiation protocol, including the timeline of culture media addition and factor incubation, as well as the RT-qPCR, ICC and WB analyses performed in this context; (b) RT-qPCR for the VM marker genes FOXA2, LMX1A, OTX2 and EN1 on total RNA isolated from wt (XM001) or NES-mScarlet #18 hiPSC-derived cells on d31 of the modified differentiation protocol; (c) RT-qPCR for the forebrain (FOXG1), ventral diencephalic (BARHL1), hindbrain (HOXA2) and diencephalic/neural rosette (PAX6) marker genes on total RNA isolated from wt (XM001) or NES-mScarlet #18 hiPSC-derived cells on d31 of the modified differentiation protocol. The values shown in (b) and (c) are the $2^{-\Delta \Delta Ct}$ ratios of the difference between cycle thresholds ($\Delta Ct$) of the corresponding marker genes and the housekeeping gene ACTB; * $p < 0.05$, *** $p < 0.001$ in the two-sample $t$-test, $n = 3$ independent differentiation experiments; (d) ICC for the detection of the VM NSC/NPC marker proteins NESTIN, LMX1, EN1/NESTIN and OTX2/NESTIN in the NES-mScarlet #18 hiPSC-derived cells on d31 of the modified differentiation protocol. Top panels are the single red (NESTIN and OTX2), green (LMX1, EN1 and NESTIN) and blue (DAPI) channel views of the merged images below. Scale bars: 100 µm.
To exclude that the generated NSCs/NPCs had acquired an alternative fate of a different brain region (fore- or hindbrain), we also monitored the expression of a forebrain-specific (FOXG1), two diencephalic (BARHL1 and PAX6) and a hindbrain-specific (HOXA2) marker gene in the differentiating cells at d31. Except for the diencephalic and neural rosette marker PAX6, which was expressed at relatively high levels in both the NES-mScarlet #18 and wt NSCs/NPCs, these cells exhibited much lower mRNA ratios of the forebrain marker FOXG1, the diencephalic marker BARHL1 and the hindbrain marker HOXA2 compared to the midbrain markers EN1 and OTX2 (Figure 4c). The transcription of the ventral diencephalic marker BARHL1 was significantly higher ($p = 0.016$) in the NES-mScarlet #18 cells compared to the wt cells.

To confirm their identity as VM NSCs/NPCs, we assessed the expression of the NSC marker proteins NESTIN and SOX2, alone or together with the midbrain markers EN1, OTX2 and the VM and mDA-specific marker LMX1, by ICC on the differentiating cells (Figure 4d and Figure S4). NESTIN and SOX2 were expressed in almost all NES-mScarlet #18-derived cells, and NESTIN co-localized with EN1 or OTX2 in most cell nuclei at d31 of the modified differentiation protocol (Figure 4d and Figure S4). The expression of the VM and mDA-specific marker LMX1, by contrast, was restricted to a subset of the differentiating cells at this stage of the protocol, consistent with the lower LMX1A mRNA ratios in these cultures (Figure 4b,d and Figure S4). We concluded that despite some variabilities in the mRNA levels of certain brain-region- and cell-type-specific marker genes between the NES-mScarlet #18-derived NSCs/NPCs and their wt counterparts, the generated NES-mScarlet hiPSCs (clone #18) are capable of differentiating under defined culture conditions into bona fide NSCs/NPCs with a VM identity.

3.4. NES-mScarlet hiPSCs Differentiate into Mature Midbrain Dopaminergic Neurons

Subsequently, we tested whether the targeted NES-mScarlet hiPSCs were also capable of generating mature mDA neurons using the modified differentiation protocol (Figure 5a). Again, we used the simultaneous differentiation of the parental wt (XM001) hiPSC line under the same conditions as a control. The identity of the generated mDA neurons was determined through detection of both generic and subset-specific marker genes and proteins for this particular neuronal cell type by RT-qPCR and ICC on d61 of the modified differentiation protocol, which was the last time point analyzed in this context (QC No. 3; Figure 5a).

The transcription of the generic neuronal marker gene TUBB3 was strongly induced in the NES-mScarlet #18 hiPSC-derived cultures, similar to their wt counterparts, at d61 of the modified protocol (Figure 5b). The generic mDA marker genes TH, PITX3, DDC and DAT (SLC6A3), by contrast, were expressed at lower ratios in the mature cells, suggesting that only a smaller proportion of all neurons in the culture dish had differentiated into the mDA cell type (Figure 5b). No significant differences in the expression levels (ratios) of these generic mDA marker genes were detected between the NES-mScarlet #18 hiPSC-derived cells relative to their wt counterparts. Although similar variabilities in the mRNA ratios of the subset-specific mDA marker genes ALDH1A1, DRD2, CCK and CALB1 were observed between the wt (XM001) and NES-mScarlet #18 hiPSC-derived cells at this stage, none of them reached statistical significance (Figure 5c). Of note, the SNC DA marker gene DRD2 and the VTA DA marker gene CALB1 were transcribed at higher ratios, whereas the SNC DA-specific marker ALDH1A1 and the VTA DA-specific marker CCK were expressed at lower ratios in the NES-mScarlet #18 hiPSC-derived cells at d61 of the modified protocol (Figure 5c). It, thus, remains to be established whether this reflects a true mDA neuron subtype-specific differentiation effect or whether these variances in gene expression levels are due to technical issues, such as distinct primer binding and amplification efficiencies.
Figure 5. NES-mScarlet hiPSCs differentiate into mature mDA neurons. (a) Schematic depiction of the modified differentiation protocol, including the timeline of culture media addition and factor incubation, as well as the RT-qPCR, ICC, WB and ELISA analyses performed in this context; (b) RT-qPCR for the generic neuron marker gene TUBB3 and the generic mDA marker genes TH, PITX3, DDC and DAT (SLC6A3) on total RNA isolated from wt (XM001) or NES-mScarlet #18 hiPSC-derived cells on d61 of the modified differentiation protocol; (c) RT-qPCR for the subset-specific mDA marker
genes ALDH1A1 and DRD2 (SNc DA neurons) or CCK and CALB1 (VTA DA neurons) on total RNA isolated from wt (XM001) or NES-mScarlet #18 hiPSC-derived cells on d61 of the modified differentiation protocol. The values shown in (b) and (c) are the 2−ΔΔCt ratios of the differences between the cycle thresholds (ΔCt) of the corresponding marker genes and the housekeeping gene ACTB; n = 3 independent differentiation experiments; (d) ICC for the detection of the generic neuron marker TUBB3 and the mDA marker TH, as well as the VTA DA-specific marker CALB1 in the NES-mScarlet #18 hiPSC-derived cells on d61 of the modified differentiation protocol. Top panels are the single green (TH and CALB1), red (TUBB3 and TH) and blue (DAPI) channel views of the merged images below. Arrows point at TH+/CALB1 double-positive cells. Scale bars: 100 µm; (e) Quantification of TH+/DAPI+ and TH+/TUBB3 + double-positive cells among all DAPI+ or TUBB3 + cells in the wt (XM001) or NES-mScarlet #18 hiPSC-derived cultures on d61 of the modified differentiation protocol; * p < 0.05 in the two-sample t-test, n = 3 independent differentiation experiments; (f) Fold change of DA release (relative to the PBS-treated cells, set as 1) after treatment of the wt (XM001) or NES-mScarlet #18 hiPSC-derived cells with 3 or 40 mM KCl on d51 of the modified differentiation protocol; * p < 0.05 in the one-sample t-test, n = 2 independent differentiation experiments.

Next, we assessed the expression of some of these marker proteins in the mature cells. The DA neuron marker TH was detected in a subset of the TUBB3-positive neurons derived from the NES-mScarlet #18 hiPSCs on d61 of their differentiation, thus confirming the previous RT-qPCR data (Figure 5d). Only very few of the TH-positive NES-mScarlet #18-derived DA neurons co-expressed the VTA DA marker CALB1 at this stage (Figure 5d). Quantification of the proportion of TH-positive cells among all DAPI-positive cells revealed that around a fifth (16.82% ± 0.95 for wt (XM001) and 19.37% ± 1.5 for NES-mScarlet #18) had acquired the DA neuron identity, whereas the proportion of TH-positive DA cells reached around one third to almost a half (31.86% ± 1.57 for wt (XM001) and 43.43% ± 2.15 for NES-mScarlet #18) of the TUBB3-positive neurons on d61 of the modified protocol (Figure 5e). Notably, the proportion of TH- and TUBB3-double-positive DA neurons was significantly higher in the NES-mScarlet #18-derived cultures compared to the wt (XM001) cultures (Figure 5e).

Additionally, we determined the ability of the mature mDA neurons (d51 of the modified protocol) to release DA under both unstimulated conditions (PBS treatment) and after stimulation with low (3 mM) or high (40 mM) KCl concentrations [32]. Upon low KCl treatment, DA release from the differentiated cells increased by almost 1.5-fold (1.31 ± 0.02-fold for wt (XM001) and 1.49 ± 0.23-fold for NES-mScarlet #18), whereas high KCl treatment led to an approx. 4 to 5-fold (3.90 ± 0.66-fold for wt (XM001) and 4.87 ± 1.35-fold for NES-mScarlet #18) and significant release of DA relative to the unstimulated condition (Figure 5f). Other catecholamines downstream of DA synthesis (norepinephrine, adrenaline and noradrenaline) were not released at detectable levels from the unstimulated and stimulated cells (data not shown). These data indicated that the targeted NES-mScarlet hiPSCs, similar to the parental wt (XM001) hiPSCs, were capable of generating mature mDA neurons using a modified monolayer protocol for the directed differentiation of these cells.

3.5. NES-mScarlet hiPSCs Are Accurate Reporter Cells of Human Neural Stem/Progenitor Cells

Given the previous results, we determined the time course and efficacy of NESTIN and mScarlet expression from the CRISPR-Cas9-targeted NES locus in the differentiating NES-mScarlet #18 hiPSCs and compared it to the parental wt (XM001) hiPSC line in the case of NESTIN. The targeted NES locus was expected to produce a bicistronic mRNA encoding the NES and mScarlet open reading frames, which gives rise to two independent proteins (NESTIN and mScarlet) upon 2A-mediated “self-cleavage” (ribosome skipping) during translation. RT-qPCR to detect NES, mScarlet and bicistronic NES-mScarlet mRNA sequences revealed that the mRNA ratios increased notoriously and peaked at d7–d11 of our modified differentiation protocol relative to the undifferentiated NES-mScarlet #18 and wt hiPSCs (Figure 6a), indicating that these cells had acquired an NSC/NPC (neuroectodermal)
identity during the first week of differentiation. After this time point (d11), the levels of NES, mScarlet and bicistronic NES-mScarlet mRNA in the differentiating NES-mScarlet #18 NSCs/NPCs decreased strongly to almost the same levels in the undifferentiated hiPSCs at d16 (Figure 6a), which coincided with the end of patterning factor treatment and the initiation of terminal differentiation in the modified protocol (Figure 5a). Thereafter, NES mRNA ratios stayed at these low levels over the remaining culture time and increased only slightly towards the end (around d61) of the differentiation protocol in the NES-mScarlet #18 but not in the wt hiPSCs (Figure 6a). By contrast, the ratios of mScarlet and bicistronic NES-mScarlet mRNA increased by d23 and remained stable at these higher levels over the next ~20 days but appeared to increase slightly again towards the end (d51–d61) of the modified differentiation procedure (Figure 6a). We concluded that the targeted NES locus generated a bicistronic NES-mScarlet mRNA whose expression accurately recapitulated the acquisition of an NSC/NPC identity by the differentiating NES-mScarlet #18 hiPSCs and their further maturation into postmitotic mDA neurons. The slight increase of bicistronic NES-mScarlet mRNA levels towards the end of the differentiation procedure might indicate the persistence of a small but detectable number of self-renewing NSCs/NPCs in the mature cultures (see below). The measured differences in ratios (2^−ddCt values) between the amplified NES, mScarlet and NES-mScarlet sequences are most likely due to different amplification efficiencies for the three primer pairs used in this experiment.

We next determined the absence of a potential fusion protein (due to missed ribosome skipping during translation) and the pattern of NESTIN and mScarlet protein expression in the differentiating NES-mScarlet #18 hiPSCs. Throughout the protocol, we only detected a high molecular weight band around 240 kDa, which is the expected size of the full-length human NESTIN protein [14], and a smaller band around 30 kDa, which corresponds to the expected size of the monomeric Scarlet protein (26.4 kDa, [23]), in the differentiating cells (Figure 6b and Figure S5). Because we did not detect any higher molecular weight band that might correspond to a fusion of these two proteins, we concluded that the NESTIN intermediate filament and mScarlet reporter were correctly processed into single proteins in the targeted NES-mScarlet #18 hiPSCs. Notably, the levels of NESTIN and mScarlet proteins in these cells also appeared to increase between d7 and d11 of the modified differentiation protocol, corresponding to the NSC/NPC stage (Figure 6b). After this time point (d11), they appeared to remain at the same levels between d16 and d31 (postmitotic precursor cell stage) but dropped noticeably at d41 and became almost undetectable at d61 (mature neuron stage) of this protocol (Figure 6b). This finding is in line with the RT-qPCR data (Figure 6a) and indicated that both NESTIN and mScarlet protein levels are downregulated to the same extent and at the same time that the NES-mScarlet #18 NSCs/NPCs acquire a mature (mDA) neuron identity.

We then assessed the fidelity of the differentiating NES-mScarlet #18 hiPSCs as a reporter for human NSCs/NPCs. Therefore, we double-labeled the differentiating cells by ICC for NESTIN and mScarlet proteins at d23 of the modified protocol (Figure 6c). This corresponds to a time point when bicistronic NES-mScarlet mRNA, as well as NESTIN and mScarlet protein levels, are already declining in the NES-mScarlet #18 NSCs/NPCs due to their differentiation into postmitotic (VM and mDA) precursors (Figure 6a,b), thus allowing for the distinction between NESTIN- and/or mScarlet-positive or -negative cells. In fact, 94.54% ± 1.63 of the NESTIN-positive cells also expressed mScarlet (i.e., they were double-positive cells), and only 5.46% ± 1.63 of the NESTIN-positive cells were mScarlet-negative, thus confirming that the vast majority of the NESTIN-positive NES-mScarlet #18 NSCs/NPCs co-expressed the reporter protein mScarlet on d23 of their differentiation (Figure 6d). Importantly, we did not detect any mScarlet-positive but NESTIN-negative cells in our cultures, indicating that the mScarlet reporter was not ectopically expressed in the NES-mScarlet #18 hiPSC-derived cells (Figure 6d). Together with the WB data, we could also rule out the persistence of mScarlet protein in NESTIN-negative cells due to different turnover kinetics for the two proteins.
Cells 2022, 11, x FOR PEER REVIEW 16 of 25

Figure 6. NES-mScarlet hiPSCs are accurate reporters of human NSCs/NPCs. (a) Time course of NES, mScarlet and bicistronic NES-mScarlet mRNA detection in differentiating wt (XM001) and NES-mScarlet #18 hiPSCs, determined by RT-qPCR on d7, d11, d16, d23, d31, d41, d51 and d61 of the modified differentiation protocol. The values shown are the fold changes (2−ΔΔCt ratios) of the differences between the cycle thresholds (ΔCt) of the corresponding amplicon and the housekeeping gene ACTB relative to undifferentiated hiPSCs, n = 3 independent differentiation experiments; (b) Western blot for the detection of full-length human NESTIN (~240 kDa) and mScarlet (~30 kDa) proteins in cell lysates from differentiating NES-mScarlet #18 hiPSCs on d7, d11, d16, d23, d31, d41, d51 and d61 of the modified differentiation protocol. Beta-actin (42 kDa) was used as a loading control; (c) ICC for the detection of the NSC/NPC marker protein NESTIN and the mScarlet reporter in the NES-mScarlet #18 hiPSC-derived cells on d23 of the modified differentiation protocol. Top panels are the single green (NESTIN), red (mScarlet) and blue (DAPI) channel views of the merged image below. Scale bars: 100 µm; (d) Quantification of mScarlet (RFP) and/or NESTIN (NES) single-and double-positive cells in the NES-mScarlet #18 hiPSC-derived cultures on d23 of the modified differentiation protocol, n = 3 independent differentiation experiments.

Lastly, we evaluated the expression of the red fluorescent reporter in living NES-mScarlet #18 hiPSC-derived cells during the course of differentiation (Figure S6). Faint mScarlet-positive cells were detected as early as d3 of the modified protocol in the differentiating NES-mScarlet #18 and NES-mScarlet #21 cultures, both homozygous for the targeted locus, by direct visualization under a fluorescence microscope (Figure S6 and data not shown). The intensity of the red mScarlet fluorescence, as well as the numbers of reporter-positive cells, increased during the subsequent days of their differentiation into NSCs/NPCs but gradually diminished as these cells become mature neurons after d31 of the modified protocol (Figure S6 and data not shown). By contrast, we could not detect any red mScarlet fluorescence in the heterozygote NES-mScarlet #23 hiPSC-derived cultures upon visual inspection under a fluorescence microscope, suggesting that one NES-mScarlet allele in the targeted cells was not sufficient for the direct (live) visualization of the mScarlet reporter (data not shown). We concluded that the NES-mScarlet #18 hiPSC line is a sufficiently accurate reporter cell line for NESTIN expression in human NSCs/NPCs, which can be visualized directly under a fluorescence microscope.
3.6. NES-mScarlet hiPSCs Are Suitable for Live Cell Imaging and Flow Cytometric Analysis and Cell Sorting

The original purpose of generating the NES-mScarlet #18 hiPSCs was the ability to combine these red fluorescent reporter cells for human NSCs/NPCs with other fluorescent (e.g., green) molecules or reporter proteins in live cell imaging, as well as the fluorescence-based flow cytometric analysis and sorting of these cells. To demonstrate the suitability of this reporter hiPSC line for combined fluorescence in live cell imaging, we used the green fluorescent Ca\(^{2+}\) indicator Fluo-8 to detect Ca\(^{2+}\)-mediated activities in the NES-mScarlet #18 hiPSC-derived cells on d31 of the modified differentiation protocol (Figure 7a). Both the green fluorescence of the Fluo-8 Ca\(^{2+}\) indicator and the red fluorescence of the mScarlet reporter in NSCs/NPCs were easily distinguishable by live cell imaging of the differentiating cultures (Figure 7b). Nevertheless, the slow Ca\(^{2+}\) transients that were observed in the cultures at this stage of their differentiation were mostly restricted to the mScarlet-negative postmitotic neuronal precursor cells present in the dish (data not shown).

Figure 7. Live cell/Ca\(^{2+}\) imaging and flow cytometric analysis of NES-mScarlet hiPSC-derived NSCs/NPCs. (a) Schematic depiction of the modified differentiation protocol including the timeline of culture media addition and factor incubation as well as the Ca\(^{2+}\) imaging and fluorescence-based flow cytometric analyses and sorting (FACS) performed in this context; (b) Live cell imaging for the detection of red fluorescent mScarlet\(^{+}\) NSCs/NPCs and the green fluorescent Ca\(^{2+}\) indicator Fluo-8 in NES-mScarlet #18 hiPSC-derived cells on d31 of the modified differentiation protocol. Top panels are the single red (mScarlet) and green (Fluo-8) channel views of the merged image below. Scale bars: 100 µm; (c) Scatter plots of the flow cytometric analysis of NES-mScarlet #18 hiPSC-derived NSCs/NPCs (pink) and their wt (XM001) counterparts (control; blue) on d11 and d23 of the modified differentiation protocol. FSC-A, amplitude of the forward scatter signal; mScarlet-A, amplitude of the mScarlet red fluorescence. Top graphs are the corresponding histograms.
Next, fluorescence-based flow cytometry was performed with differentiating *wt* (XM001; control) and *NES*-mScarlet #18 cells on d11 and d23 of the modified protocol (Figure 7a). Differentiation d11 corresponded with the NSC/NPC stage and peak expression of both NESTIN and the mScarlet reporter, whereas d23 represented a later stage at which bicistronic *NES-mscarlet* mRNA levels were already declining and a few NESTIN-positive but mScarlet-negative cells were detected in the differentiating cultures (Figure 6). At both time points, more than 99% of the analyzed cells expressed the red fluorescent mScarlet reporter (99.95% at d11 and 99.96% at d23), indicating that the NSC/NPC reporter population can be sorted to a very high purity at the relevant stages using this approach (Figure 7c and Figure S7). Altogether, we concluded that the *NES*-mScarlet #18 hiPSCs are a reliable and accurate reporter cell line for human NSCs/NPCs that can be used in combination with other fluorophores for the direct identification or isolation of these cells in live cell imaging or fluorescence-based flow cytometric analyses and sorting assays. Moreover, the *NES*-mScarlet #18 NSCs/NPCs can be differentiated into mature and functional mDA neurons to the same extent as their parental (XM001) hiPSC line, as one example for a downstream application of these cells.

4. Discussion

We report the successful generation of a novel red fluorescent reporter hiPSC line (*NES*-mScarlet #18) for the direct detection in the culture dish and isolation to a high purity of human NSCs/NPCs. This was achieved by the introduction of a 2A self-cleaving peptide followed by the mScarlet reporter at the C-terminus of the well-characterized stem cell marker protein NESTIN [14], using CRISPR-Cas9-mediated homology-directed repair [33]. We chose this targeting strategy of the *NES* locus for several reasons. Firstly, two green fluorescent NESTIN reporter PSC lines are already available in the human context [17,18], but to our knowledge, a corresponding red fluorescent reporter PSC line has not been generated so far. The new *NES*-mScarlet hiPSC line, thus, expands the current tool set of human NESTIN reporter cell lines. The mScarlet fluorophore is an extremely bright (high fluorescence lifetime and quantum yield) and truly monomeric (no accumulation in organelles) RFP that was selected based on these particular spectral and biochemical as well as additional properties, including its tolerance to acidic environments and very low cytotoxicity [23]. Secondly, our approach avoided the synthesis of an unphysiological NESTIN-reporter fusion protein (as in the CRISPR-Cas9-targeted green fluorescent hiPSC line KSCBi005-A-1, [17]) and allowed the stoichiometric production of independent NESTIN and mScarlet proteins in the targeted cells. Thirdly, targeting the endogenous *NES* locus in the hiPSCs circumvented the problems associated with the generation of transgenic hiPSC lines using the well characterized second intron of the human *NES* gene [18,34]. These include restriction to the neural lineage and random integration of the transgene into the cell’s genome at variable copy numbers, often resulting in ectopic or silenced expression of the reporter due to positional effects [14,18]. Lastly, the absence of a selection marker in the targeted *NES* locus ensured the unperturbed transcription and translation from this locus. As expected, the *NES*-mScarlet hiPSCs retained a normal karyotype and maintained their pluripotency over several rounds of expansion.

We subsequently devised a modified protocol from published versions [13,25,26] to direct the newly generated *NES*-mScarlet hiPSCs into the VM NSC/NPC fate. Using this paradigm, the *NES*-mScarlet hiPSCs differentiated robustly and reproducibly into NSCs/NPCs of a VM identity, which was determined by their VM-specific marker gene and protein expression. Moreover, the pre-patterned VM NSCs/NPCs were capable of generating fully mature and functional mDA neurons, characterized by the expression of generic and subset-specific mDA marker genes and proteins, and by the release of DA under basal conditions and upon KCl stimulation. The numbers of TH-positive DA cells (~20%) or neurons (30–45%) in these cultures were within the expected range (7–70% around d50 of differentiation) and corresponded well with the published data [8,35]. However, the mRNA levels of the mDA-specific marker *LMX1A* were rather low compared to the other
VM-specific genes, and this protein was only detected in a subset of the NES-mScarlet hiPSC-derived VM NSCs/NPCs. Furthermore, unwanted forebrain (FOXG1, BARHL1, PAX6) and hindbrain (HOXA2) marker genes were still expressed at detectable levels in the differentiating cells using this modified protocol. Both observations are in line with a newer report showing that a bi-phasic modulation of WNT signaling (via CHIR99021, initially low and later high) is necessary during the initial steps of human PSC conversion to a VM/mDA neural fate for the generation of bona fide VM/mDA NSCs/NPCs expressing high levels of LMX1A and low to absent levels of the aforementioned marker genes for other brain regions [29]. Conversely, the mature mDA neurons derived from the human VM/mDA NSCs/NPCs with this modified WNT signaling protocol exhibited rather low mRNA levels for both generic and subset-specific markers of these neurons [29], suggesting that the high WNT signaling levels in the second phase of this paradigm suppressed the generation of genuine and possibly subset-specific (SNc or VTA) mDA neurons. In fact, it was recently shown that inhibition of WNT signaling during the late phase of VM/mDA NSC/NPC patterning (after initially higher WNT signaling levels compared to our protocol [26]) promotes the preferential derivation of SNc DA neurons from human PSCs, whereas high WNT signaling levels during this phase force them into the VTA DA neuron identity [36]. We therefore speculate that an improved protocol, which precisely recapitulates the time course of WNT signaling during mDA neuron development in vivo [12,37] might be able to direct our NES-mScarlet hiPSCs into a genuine and possibly also subtype-specific mDA neuron identity. This will be assessed in future experiments.

We show that the new NES-mScarlet #18 hiPSC line is an accurate red fluorescent reporter cell line for human NSCs/NPCs and potentially also for all kinds of NESTIN-positive stem and progenitor cells. Using the modified protocol mentioned above, we demonstrate that the NES-mScarlet #18 hiPSCs reliably and reproducibly up- or downregulate the red fluorescent mScarlet reporter in the same temporal pattern as NESTIN is expressed from the native NES promoter during the course of their differentiation. Manual cell counting revealed that most (~95%) of the NESTIN-positive NES-mScarlet #18 hiPSC-derived NSCs/NPCs at d23 of the modified differentiation protocol co-expressed the mScarlet reporter. The few (~5%) NESTIN-positive but mScarlet-negative cells detected in this experimental paradigm might have been assigned erroneously to this category because of the weak to very weak expression of the reporter protein in these cells. Indeed, fluorescence-based flow cytometry of the NES-mScarlet #18 hiPSC-derived cultures on the same day (d23) of the modified differentiation protocol revealed that more than 99% of these cells are mScarlet-positive and can, thus, be sorted to a very high degree of purity. Most importantly, we were unable to detect any ectopic mScarlet-positive but NESTIN-negative cells in the manual cell counting paradigm, and Western blotting confirmed these data. We can, therefore, conclude that the expression of the red fluorescent mScarlet reporter faithfully recapitulates the expression of endogenous NESTIN in our new NES-mScarlet #18 hiPSC line, thus circumventing the problems associated with other NESTIN reporter lines. These include the ectopic expression of the reporter protein in transgenic PSC lines, probably because of positional effects after random integration of the transgene [18], and the prolonged detection of the green fluorescent reporter protein because of its low turnover in the cells [14,17].

Finally, we show that the NES-mScarlet #18 hiPSC line is a versatile tool for the direct identification and tracking of human NSCs/NPCs in the culture dish and their fluorescence-based flow cytometric analysis and sorting, which can be easily combined with other fluorophores of distinct spectral properties, e.g., in the blue, green or far-red range. Here, we used the red mScarlet fluorescence and the green Ca$^{2+}$ indicator Fluo-8 to detect potential Ca$^{2+}$ activities (transients and spikes) in the differentiating cells, namely VM/mDA NSCs/NPCs (mScarlet-positive) or postmitotic mDA precursors and neurons (mScarlet-negative). However, the use of this novel red fluorescent reporter hiPSC line might be extended to any other application in this regard. Furthermore, our analyses were focused on this type of neural cells and the in vitro generation of human NSCs/NPCs with a VM and mDA identity. Because NESTIN is expressed in several other tissue and stem
cell types of the body [14], and because the NES promoter, first intron and second intron (harboring a muscle-specific and a CNS-specific enhancer, respectively [34,38]) were left intact in the targeted NES-mScarlet #18 hiPSC line, it is reasonable to assume that this novel reporter hiPSC line might also be useful for studies in other stem cell and regenerative medicine fields. This includes, but is not restricted to, the vast area of mesenchymal and hematopoietic stem cells likewise expressing this intermediate filament and implicated in several bone marrow malignancies [14].

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/cells11020268/s1, Figure S1: PCR genotyping of NES-mScarlet hiPSC clones using primer pairs P5/P6 and P7/8, Figure S2: Karyotyping of NES-mScarlet hiPSC clones #7, #18, #21 and #23 using an Illumina platform for SNP analysis, Figure S3: Analysis of off-target sites in NES-mScarlet hiPSC clones, Figure S4: NES-mScarlet hiPSCs differentiate into genuine VM NSCs/NPCs, Figure S5: NES-mScarlet hiPSCs are accurate reporters of human NSCs/NPCs, Figure S6: Live cell imaging of NES-mScarlet hiPSC clones under various conditions, Figure S7: Gate setting of the flow cytometric analysis of NES-mScarlet #18 hiPSC-derived NSCs/NPCs and their wt (XM001) counterparts (control) on d11 and d23 of the modified differentiation protocol.

**Author Contributions:** Conceptualization, N.P.; methodology, P.N. and R.K.; validation, P.N. and A.Z.; formal analysis, P.N.; investigation, P.N., A.Z., S.B. and R.F.; writing—original draft preparation, P.N., R.K. and N.P.; writing—review and editing, N.P.; visualization, P.N.; supervision, R.K. and N.P.; funding acquisition, R.K. and N.P. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Deutsche Forschungsgemeinschaft (DFG), grant number KU 3389/2-1 to R.K. and grant number PR 629/3-1 (Projektnummer 408031320) to N.P.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the Ärztekammer Westfalen-Lippe and Westfälische Wilhelms Universität Münster (protocol code 2019-426-f-S on 17 September 2019).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data is contained within the article and Supplementary Material.

**Acknowledgments:** We thank Xianming Wang, Shen Chen and Heiko Lickert (HMGU, Munich) for the XM001 hiPSCs, Sebastian Diecke and Claudia Schara (MDC stem cell core facility) for karyotype analysis, Hans Peter Rahn (MDC flow cytometry facility) for flow cytometry service, Agnes Bryniok (HSHL) for help with the hiPSC culture and Olga Rempel (HSHL) for excellent technical assistance.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**Appendix A**

**NES-mScarlet Vector Sequence (6151 bp)**

CTAAATTGTAAGCCGTATAATTTTGTAAAAATTCGCCTTAAATTTTTGTATTTAATCA
GCTCA-TTTTTTAACAAATAGGCCAAATCGGCAAAATCCCTTTATAAATCAAAAGAA
TAGACCCGAGTTAAGGTGATGAGTGCCTCTGCATACAGGGGGGTCTGCATTTTCGAG
TGCGCAACGTGGGGAAGGGCGTTTGGGTGCGCCCTTCTGCTATACGCCACGGCT
GGCGAAAGGAGGGATG-TCGTACAAGGGCATTAAGTGGGTAACGCCAGGGTTTTCC
CAGTCACGACGTTGAAACAGCGCGCATGAGCGCGACGTAATACGACTCACTAT
AGGGCGAATTGGCCAAAGGCCGTCAAGGGCGCTAGGCGCGCCAAACGCTTCACCTT
GAAAGAGGAGAGATTTTGGAGCAGCGTAAAGGGTCTAGCGGGTGGGGAAGGCTGAGA
GACCTAGAAGAGCGAGTGTCTCGGGGC-AGAGTTTCCGGCGTCGGGGAA
GAGCCGGAACTGGCGGCGGCGGAAGGGGAGTTGGGTTCTGGG

---

**Vector Sequence (6151 bp)**

CTAAATTGTAAGCCGTATAATTTTGTAAAAATTCGCCTTAAATTTTTGTATTTAATCA
GCTCA-TTTTTTAACAAATAGGCCAAATCGGCAAAATCCCTTTATAAATCAAAAGAA
TAGACCCGAGTTAAGGTGATGAGTGCCTCTGCATACAGGGGGGTCTGCATTTTCGAG
TGCGCAACGTGGGGAAGGGCGTTTGGGTGCGCCCTTCTGCTATACGCCACGGCT
GGCGAAAGGAGGGATG-TCGTACAAGGGCATTAAGTGGGTAACGCCAGGGTTTTCC
CAGTCACGACGTTGAAACAGCGCGCATGAGCGCGACGTAATACGACTCACTAT
AGGGCGAATTGGCCAAAGGCCGTCAAGGGCGCTAGGCGCGCCAAACGCTTCACCTT
GAAAGAGGAGAGATTTTGGAGCAGCGTAAAGGGTCTAGCGGGTGGGGAAGGCTGAGA
GACCTAGAAGAGCGAGTGTCTCGGGGC-AGAGTTTCCGGCGTCGGGGAA
GAGCCGGAACTGGCGGCGGCGGAAGGGGAGTTGGGTTCTGGG
Appendix B

Table A1. Composition of all media used for hiPSC culture and differentiation in this work.

| Medium Name | Added Factors | Ingredients | Final Concentration |
|-------------|---------------|-------------|---------------------|
| hiPSC-medium | StemMACSTM iPS-Brew medium | 1x | |
| | DMEM:F12 and Neurobasal | 1:1 mixture | |
| | N-2 supplement | 1% vol/vol | |
| | GlutaMAX | 1% vol/vol (2 mM) | |
| | Penicillin/streptomycin | 0.2% vol/vol | |
| | SB431542 (TGFβ inhibitor) | 10 µM | |
| N2 medium | Recombinant human Noggin (BMP inhibitor) | 100 ng/mL | |
| | Recombinant human SHH-C24II | 375 ng/mL | |
| | CHIR99021 (GSK3β inhibitor) | 0.6 µM | |
| Freezing medium | DMEM:F12 and Neurobasal | 1:1 mixture | |
| | B-27 supplement without vitamin A | 2% vol/vol | |
| | GlutaMAX | 1% vol/vol (2 mM) | |
| | DMSO | 10% vol/vol | |
| | Neurobasal | 1% vol/vol | |
| | GlutaMAX | 0.2% vol/vol | |
| B27 medium | Recombinant human FGF8b | 100 ng/mL | |
| | CHIR99021 (GSK3β inhibitor) | 0.6 µM | |
| | Recombinant human GDNF | 20 ng/mL | |
| | L-Ascorbic acid | 0.2 µM | |
| | N-[3,5-difluorophenyl]acetyl]-l-alanyl-2-phenylglycine-1,1-dimethylethyl ester (DAPT) | 1 µM | |

References

1. Kelava, I.; Lancaster, M.A. Stem Cell Models of Human Brain Development. Cell Stem Cell 2016, 18, 736–748. [CrossRef]
2. Kim, J.; Koo, B.-K.; Knoblich, J.A. Human organoids: Model systems for human biology and medicine. Nat. Rev. Mol. Cell Biol. 2020, 21, 571–584. [CrossRef]
3. Rowe, R.G.; Daley, G.Q. Induced pluripotent stem cells in disease modelling and drug discovery. Nat. Rev. Mol. Cell Biol. 2009, 10, 377–388. [CrossRef]
4. Sternebeck, J.L.; Reinhardt, P.; Scholer, H.R. Investigating human disease using stem cell models. Nat. Rev. Genet. 2014, 15, 625–639. [CrossRef]
5. Goldman, S.A. Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking. Cell Stem Cell 2016, 18, 174–188. [CrossRef]
6. Parmar, M.; Greailish, S.; Henchcliffe, C. The future of stem cell therapies for Parkinson disease. Nat. Rev. Neurosci. 2020, 21, 103–115. [CrossRef]
7. Balestrino, R.; Schapira, A.H.V. Parkinson disease. Eur. J. Neurol. 2020, 27, 27–42. [CrossRef]
8. Kim, T.W.; Koo, S.Y.; Studer, L. Pluripotent Stem Cell Therapies for Parkinson Disease: Present Challenges and Future Opportunities. Front. Cell Dev. Biol. 2020, 8, 729. [CrossRef]
9. Parmar, M. Towards stem cell based therapies for Parkinson’s disease. Development 2018, 145, dev156117. [CrossRef]
10. Poulin, J.-F.; Gaertner, Z.; Moreno-Ramos, O.A.; Awatramani, R. Classification of Midbrain Dopamine Neurons Using Single-Cell Gene Expression Profiling Approaches. Trends Neurosci. 2020, 43, 155–169. [CrossRef]
11. Biaess, S.; Ang, S.-L. Genetic control of midbrain dopaminergic neuron development. Wiley Interdiscip. Rev. Dev. Biol. 2015, 4, 113–134. [CrossRef]
12. La Manno, G.; Gyllborg, D.; Codeluppi, S.; Nishimura, K.; Salto, C.; Zeisel, A.; Borm, L.E.; Stott, S.R.W.; Toledo, E.M.; Villaescusa, J.C.; et al. Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells. Cell 2016, 167, 566–580. [CrossRef]
13. Nolbrant, S.; Heuer, A.; Parmar, M.; Kirkeby, A. Generation of high-purity ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation. Nat. Protoc. 2017, 12, 1962–1979. [CrossRef]
14. Bernal, A.; Arranz, L. Nestin-expressing progenitor cells: Function, identity and therapeutic implications. *Cell. Mol. Life Sci.* 2018, 75, 2177–2195. [CrossRef]

15. Kim, K.; Higashi, M.; Fumino, S.; Tajiri, T. Derivation of neural stem cells from human teratomas. *Stem Cell Res.* 2019, 41, 101633. [CrossRef]

16. Eze, U.C.; Bhaduri, A.; Haeussler, M.; Nowakowski, T.J.; Kriegstein, A.R. Single-cell atlas of early human brain development highlights heterogeneity of human neuroepithelial cells and early radial glia. *Nat. Neurosci.* 2021, 24, 584–594. [CrossRef]

17. Lee, Y.; Choi, H.Y.; Kwon, A.; Park, H.; Park, M.; Kim, Y.-O.; Kwak, S.; Koo, S.K. Generation of a NESTIN–EGFP reporter human induced pluripotent stem cell line, KSCB1005-A1, using CRISPR/Cas9 nuclease. *Stem Cell Res.* 2019, 40, 101554. [CrossRef]

18. Noisa, P.; Urrutikoetxea-Uruegian, A.; Li, M.; Cui, W. Generation of human embryonic stem cell reporter lines expressing GFP specifically in neural progenitors. *Stem Cell Rev. Rep.* 2010, 6, 438–449. [CrossRef]

19. Wang, X.; Sterr, M.; Burtscher, I.; Chen, S.; Hieronimus, A.; Machicao, F.; Staiger, H.; Häring, H.-U.; Lederer, G.; Meitinger, T.; et al. Genome-wide analysis of PDX1 target genes in human pancreatic progenitors. *Mol. Metab.* 2018, 9, 57–68. [PubMed]

20. Yumlu, S.; Bashir, S.; Stumm, J.; Kühn, R. Efficient Gene Editing of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9. *Methods Mol. Biol.* 2019, 1961, 137–151. [CrossRef]

21. Li, X.-L.; Li, G.-H.; Fu, J.; Fu, Y.-W.; Zhang, L.; Chen, W.; Arakaki, C.; Zhang, J.-P.; Wen, W.; Zhao, M.; et al. Highly efficient genome editing via CRISPR-Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression. *Nucleic Acids Res.* 2018, 46, 10195–10215. [CrossRef]

22. Fang, J.; Qian, J.-J.; Yi, S.; Harding, T.C.; Tu, G.H.; VanRoey, M.; Jooss, K. Stable antibody expression at therapeutic levels using the 2A peptide. *Nat. Biotechnol.* 2005, 23, 584–590. [CrossRef]

23. Bindels, D.S.; Haarboeck, L.; van Weeren, L.; Postma, M.; Wiese, K.E.; Mastop, M.; Aumonier, S.; Gotthard, G.; Royant, A.; Hink, M.A.; et al. mScarlet: A bright monomeric red fluorescent protein for cellular imaging. *Nat. Methods* 2017, 14, 53–56. [CrossRef] [PubMed]

24. Haeussler, M.; Schöning, K.; Eckert, H.; Eschstruth, A.; Mianné, J.; et al. Single-cell atlas of early human brain development reveals highly serendipity and reproducibility: Pluripotent stem cells as experimental systems for intellectual and developmental disorders. *ASN Neuro* 2020, 12, 1–17. [CrossRef]

25. de Rus Jacquet, A. Preparation and Co-Culture of iPSC-Derived Dopaminergic Neurons and Astrocytes. *Curr. Protoc. Cell Biol.* 2019, 85, e98. [CrossRef]

26. Kim, T.W.; Piao, J.; Koo, S.Y.; Kriks, S.; Chung, S.Y.; Betel, D.; Socci, N.D.; Choi, S.J.; Zabierowski, S.; Dubose, B.N.; et al. Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use. *Cell Stem Cell* 2021, 28, 343–355. [CrossRef]

27. Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. *Nat. Protoc.* 2008, 3, 1101–1108. [CrossRef]

28. Anderson, N.C.; Chen, P.-F.; Meganathan, K.; Afshar Saber, W.; Petersen, A.J.; Bhattacharyya, A.; Kroll, K.L.; Sahin, M. Balancing serendipity and reproducibility: Pluripotent stem cells as experimental systems for intellectual and developmental disorders. *Stem Cell Rep.* 2021, 16, 1446–1457. [CrossRef]

29. Kim, T.W.; Piao, J.; Koo, S.Y.; Kriks, S.; Chung, S.Y.; Betel, D.; Socci, N.D.; Choi, S.J.; Zabierowski, S.; Dubose, B.N.; et al. Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use. *Cell Stem Cell* 2021, 28, 343–355. [CrossRef]

30. Fischer, T.; Faus-Kessler, T.; Welzl, G.; Simeone, A.; Wurst, W.; Prakash, N. Fgf15-mediated control of neurogenic and proneural gene expression regulates dorsal midbrain neurogenesis. *Dev. Biol.* 2011, 350, 496–510. [CrossRef]

31. Carola, G.; Malagarriga, D.; Soleihlavoup, C.; Travaglio, M.; Sherez, S.; Peltrini, R.; Patrick, K.; Labas, V.; Combes-Soia, I.; et al. Parkinson’s disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration. *NPJ Parkinsons Dis.* 2021, 7, 55. [CrossRef]

32. Rienecker, K.D.A.; Poston, R.G.; Saha, R.N. Merits and Limitations of Studying Neuronal Depolarization-Dependent Processes Using Elevated External Potassium. *ASN Neuro* 2020, 12, 1–17. [CrossRef]

33. Heidenreich, M.; Zhang, F. Applications of CRISPR-Cas systems in neuroscience. *Nat. Rev. Neurosci.* 2016, 17, 36–44. [CrossRef]

34. Lothian, C.; Prakash, N.; Lendahl, U.; Wahlström, G.M. Identification of both general and region-specific embryonic CNS enhancer regulatory elements in the nestin gene. *Exp. Cell Res.* 2019, 381, 509–519. [CrossRef]

35. Li, W.; Chen, S.; Li, Y.-Y. Human induced pluripotent stem cells in Parkinson’s disease: A novel cell source of cell therapy and disease modeling. *Prog. Neurobiol.* 1994, 48, 137–151. [CrossRef]

36. Nouri, P.; Götz, S.; Rauser, B.; Immer, M.; Peng, C.; Trümbach, D.; Kempny, C.; Lechermeier, C.G.; Bryniok, A.; Dlugos, A.; et al. Dose-Dependent and Subset-Specific Regulation of Midbrain Dopaminergic Neuron Differentiation by LEF1-Mediated WNT1/b-Catenin Signaling. *Front. Cell Dev. Biol.* 2020, 8, 587778. [CrossRef]

37. Zimmerman, L.; Lendahl, U.; Cunningham, M.; McKay, R.; Parr, B.; Gavin, B.; Mann, J.; Vassileva, G.; McMahon, A. Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells or muscle precursors. *Neuron* 1994, 12, 11–24. [CrossRef]